| Jun 17 |
ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial
|
| Jun 15 |
ALS therapy market seen increasing to nearly $1.3B by 2029
|
| Jun 14 |
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
|
| Jun 14 |
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
|
| Jun 13 |
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
|
| Jun 12 |
Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
|
| Jun 12 |
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
|
| Jun 11 |
Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
|
| Jun 11 |
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
|
| Jun 11 |
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
|
